Adil Daud

Adil Daud is a Professor at the University of California San Francisco (UCSF), where he co-directs the melanoma program and leads early-phase clinical trials focused on immunotherapy for cancer, particularly melanoma. His work emphasizes PD-1 antibody therapy and mechanisms of resistance, including site-specific immunity. He collaborates with colleagues such as Michael Rosenblum, Max Krummel, and Jeff Bluestone, as well as national melanoma experts.

• Education: Postdoctoral Fellow at Cleveland Clinic Foundation (1987-1990); Research Assistant at Indiana University Medical Center (1990-1994); Residency in Internal Medicine (1994-1997); Fellowship in Hematology/Oncology at Memorial Sloan-Kettering (1997-2000).

Daud's research spans immunotherapy, tumor microenvironment modulation, and clinical trial design for melanoma. His recent work explores intratumoral therapies, T cell exhaustion, and biomarker discovery using single-cell and genomic analyses. Publications highlight advancements in PD-1 resistance, combination treatments, and long non-coding RNA targets in NRAS-driven melanoma.

His clinical trials, such as KEYNOTE-006 with 10-year follow-up data, demonstrate long-term efficacy of pembrolizumab over ipilimumab. Collaborative studies investigate immune checkpoint crosstalk (e.g., IFN-γ vs. MHC-I), electroporation techniques, and novel bispecific antibodies like SGN-BB228.

• Scientific Awards: Young Investigator Award (ASCO, 2000); Clinical Trial Award at Moffitt Cancer Center (2005-2007); Best Doctors in America (2007-2010).